Intrinsic Value

The intrinsic value of ONWARD Medical NV (63E) under the Base Case is 0.852 EUR per share. Compared with the current market price of 1.366 EUR, the stock appears Overvalued by 38% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

63E Intrinsic Value
€0.852
Overvaluation 38%
Intrinsic Value
Price €1.366

63E is cheaper than usual. Still overvalued, but less so than on 80% of days in the past 5 years.

Alert me when 63E is below its intrinsic value
Today €0.682 · 50.1% below the current price
Alternatives to 63E

Fundamental Analysis

What ONWARD Medical Does

Health Care

ONWARD Medical develops implantable and external neurostimulation devices that are designed to help people with spinal cord injury and related movement disorders recover motion and function. Its main products are built around electrical stimulation of the spinal cord, which aims to activate nerve pathways that still exist but no longer work properly after injury. The company focuses on therapies that can support walking, hand use, blood pressure control, and other functions affected by spinal cord damage.

Headquarters
Netherlands NL
Employees
137
IPO date
Oct 21, 2021
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · November 3, 2026

ONWARD paired continued ARC-EX adoption with progress across its ARC-IM pipeline, while reimbursement processes are extending some sales timing.

Open the earnings call
Stock, day of the call
−11.5%
View Earnings Call

Past 12 months

Continue 63E Research

Decided on ONWARD Medical? Get an email when 63E reaches the price you’d buy at. Free with an account.

Other ONWARD Medical listings

What is the Intrinsic Value of one 63E stock?

The intrinsic value for ONWARD Medical NV (63E) under the Base Case is 0.852 EUR.

Is 63E stock undervalued or overvalued?

Compared with the current market price of 1.366 EUR, the stock appears Overvalued by 38% .

How reliable are our estimates? See how past valuations played out
Back to Top